Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Adjuvant alectinib verbetert DFS, maar effect op OS nog onduidelijk
mei 2024 | Longoncologie